Dennis Stephens
Memorial Sloan Kettering Cancer Center
14 Papers
32 Citations
Dennis Stephens is an academic researcher from Memorial Sloan Kettering Cancer Center. The author has contributed to research in topics: Medicine & Gene. The author has an hindex of 7, co-authored 11 publications.
Chat about Author
Papers
Antibody-mediated thyroid dysfunction during T-cell checkpoint blockade in patients with non-small-cell lung cancer.
Juan C. Osorio,Ai Ni,Jamie E. Chaft,R. Pollina,M.K. Kasler,Dennis Stephens,Carlos J. Rodriguez,L. Cambridge,Hira Rizvi,Jedd D. Wolchok,Taha Merghoub,Charles M. Rudin,Stephanie Fish,Matthew D. Hellmann,Matthew D. Hellmann +14 more
TL;DR: Thyroid dysfunction during pembrolizumab treatment of NSCLC is common and is characterized by early-onset, frequently preceded by transient hyperthyroidism, closely associated with anti-thyroid antibodies, and may be associated with improved outcomes.
628
DNA Sensing in Mismatch Repair-Deficient Tumor Cells Is Essential for Anti-tumor Immunity.
Changzheng Lu,Junhong Guan,Steve Lu,Qihuang Jin,Benoit Rousseau,Tianshi Lu,Dennis Stephens,Hongyi Zhang,Jiankun Zhu,Mingming Yang,Zhenhua Ren,Yong Liang,Zhida Liu,Chuanhui Han,Longchao Liu,Xuezhi Cao,Anli Zhang,Jian Qiao,Kimberly Batten,Mingyi Chen,Diego H. Castrillon,Tao Wang,Bo Li,Luis A. Diaz,Guo Min Li,Yang Xin Fu +25 more
TL;DR: Using tumor models defective in the MMR gene Mlh1, it is shown that dMLH1 tumor cells accumulate cytosolic DNA and produce IFN-β in a cGAS-STING-dependent manner, which renders d MLH1 tumors slowly progressive and highly sensitive to checkpoint blockade.
211
Enhanced specificity of clinical high-sensitivity tumor mutation profiling in cell-free DNA via paired normal sequencing using MSK-ACCESS.
A. Rose Brannon,Gowtham Jayakumaran,Monica Diosdado,Juber Patel,Anna Razumova,Yu Hu,Fanli Meng,Mohammad Haque,Justyna Sadowska,Brian J. Murphy,Tessara Baldi,Ian Johnson,Ryan Ptashkin,Maysun Hasan,Preethi Srinivasan,Anoop Balakrishnan Rema,Ivelise Rijo,Aaron Agarunov,Helen Won,Dilmi Perera,David N Brown,Aliaksandra Samoila,Xiaohong Jing,Erika Gedvilaite,Julie L. Yang,Dennis Stephens,Jenna-Marie Dix,Nicole DeGroat,Khedoudja Nafa,Aijazuddin Syed,Alan Li,Emily S. Lebow,Anita S. Bowman,Donna C. Ferguson,Ying Liu,Douglas A. Mata,Rohit Sharma,Soo-Ryum Yang,Tejus Bale,Jamal Benhamida,Jason C. Chang,Snjezana Dogan,Meera Hameed,Jaclyn F. Hechtman,Christine Moung,Dara S. Ross,Efsevia Vakiani,Chad M. Vanderbilt,Jinjuan Yao,Pedram Razavi,Lillian M. Smyth,Sarat Chandarlapaty,Gopa Iyer,Wassim Abida,James J. Harding,Benjamin A. Krantz,Eileen M. O'Reilly,Helena A. Yu,Bob T. Li,Charles M. Rudin,Luis A. Diaz,David B. Solit,Maria E. Arcila,Marc Ladanyi,Brian Loomis,Dana W.Y. Tsui,Michael F. Berger,Ahmet Zehir,Ryma Benayed +68 more
TL;DR: MSK-ACCESS as mentioned in this paper is an NGS assay for detection of very low frequency somatic alterations in 129 genes and achieved 92% sensitivity in de-novo mutation calling down to 0.5% allele frequency and 99% for a priori mutation profiling.
Genome-wide mutational signatures in low-coverage whole genome sequencing of cell-free DNA
Jonathan C. M. Wan,Dennis Stephens,Lingqi Luo,James R. White,Caitlin Stewart,Benoit Rousseau,Dana W.Y. Tsui,Luis A. Diaz +7 more
TL;DR: In this paper , the authors used machine learning to identify pathological and physiological mutational signatures in plasma whole-genome sequencing (WGS) data and showed that patients with stage I-IV cancer can be distinguished from healthy individuals with an Area Under the Curve of 0.96.
Cell‐free DNA profiling in retinoblastoma patients with advanced intraocular disease: An MSKCC experience
Prachi Kothari,Francesco Marass,Francesco Marass,Julie L. Yang,Caitlin Stewart,Dennis Stephens,Juber Patel,Maysun Hasan,Xiaohong Jing,Fanli Meng,Jeanette Enriquez,Kety Huberman,Agnes Viale,Jasmine H. Francis,Jasmine H. Francis,Michael F. Berger,Michael F. Berger,Neerav Shukla,David H. Abramson,David H. Abramson,Ira J. Dunkel,Ira J. Dunkel,Dana W.Y. Tsui,Dana W.Y. Tsui +23 more
TL;DR: Whether sufficient tumorderived cfDNA is shed in plasma from retinoblastoma tumors to enable noninvasive RB1 mutation detection is analyzed.
43